In times of increasing costs for health insurances, obstructive lung diseases are a burden for both the patients and the economy. Pulmonary symptoms of asthma and chronic obstructive pulmonary disease (COPD) are similar; nevertheless, the diseases differ in pathophysiology and therapeutic approaches. Novel therapeutics are continuously developed, and nonhuman primates (NHPs) provide valuable models for investigating novel biologicals regarding efficacy and safety. This review discusses the role of nonhuman primate models for drug development in asthma and COPD and investigates whether alternative methods are able to prevent animal experiments.
Keyphrases
- chronic obstructive pulmonary disease
- lung function
- end stage renal disease
- ejection fraction
- newly diagnosed
- public health
- chronic kidney disease
- cystic fibrosis
- pulmonary hypertension
- peritoneal dialysis
- air pollution
- small molecule
- mental health
- prognostic factors
- physical activity
- depressive symptoms
- risk factors
- patient reported outcomes
- sleep quality
- health information
- human health